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A B S T R A C T
Purpose
To assess the effectiveness of mindfulness-based stress reduction (MBSR) for mood, breast- and
endocrine-specific quality of life, and well-being after hospital treatment in women with stage 0 to
III breast cancer.
Patients and Methods
A randomized, wait-listed, controlled trial was carried out in 229 women after surgery, chemo-
therapy, and radiotherapy for breast cancer. Patients were randomly assigned to the 8-week
MBSR program or standard care. Profile of Mood States (POMS; primary outcome), Functional
Assessment of Cancer Therapy–Breast (FACT-B), Functional Assessment of Cancer Therapy–
Endocrine Symptoms (FACT-ES) scales and the WHO five-item well-being questionnaire (WHO-5)
evaluated mood, quality of life, and well-being at weeks 0, 8, and 12. For each outcome measure,
a repeated-measures analysis of variance model, which incorporated week 0 measurements as a
covariate, was used to compare treatment groups at 8 and 12 weeks.
Results
There were statistically significant improvements in outcome in the experimental group
compared with control group at both 8 and 12 weeks (except as indicated) for POMS total
mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks
only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional
Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and
functional well-being), and WHO-5.
Conclusion
MSBR improved mood, breast- and endocrine-related quality of life, and well-being more
effectively than standard care in women with stage 0 to III breast cancer, and these results
persisted at three months. To our knowledge, this study provided novel evidence that MBSR can
help alleviate long-term emotional and physical adverse effects of medical treatments, including
endocrine treatments. MBSR is recommended to support survivors of breast cancer.
J Clin Oncol 30:1335-1342. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Approximately 550,000people are livingwith breast
cancerintheUnitedKingdom.1Surgery,chemother-
apy, radiotherapy, and hormonal treatments for
breast cancer have physical and psychological se-
quelae that last from months to years beyond
hospitalization.2-4 Symptoms such as anxiety,5 de-
pression,6 pain,7 fatigue,2 endocrine symptoms,8
and insomnia9 can reduce quality of life.
Psychoeducational support and integrative
therapies for survivors, including the development
of self-management skills to cope better, are un-
evenly providedworldwide.One increasingly popu-
lar approach to support people who are living with
cancer is the cultivation of mindfulness.10-12 Mind-
fulness (ie, bringing attention and awareness to each
moment in a nonjudgemental way) is a way of be-
ing.13 Its origins are clearest inBuddhist philosophy,
but elements of mindfulness are used in psycholog-
ical approaches includingcognitive-behavioral ther-
apy. Mindfulness can be taught via a systematic
8-weekmindfulness-based stress reduction (MBSR)
program.13 The benefits of MBSR have been re-
searched in long-term health conditions includ-
ing chronic pain,14-16 anxiety,17,18 fibromyalgia,19
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psychological symptoms,20 psoriasis,21 increased stress and mood in
outpatients with general cancer,10,11 and insomnia,10-12 but method-
ological rigor was limited in all studies either as a result of problems,
such as small sample sizes,10-12 no randomization, or intention-to-
treat analysis, or impeded by poor reporting. A review of 13 articles
that evaluated mindfulness-based interventions and cancer since
200722 citedonly one randomized controlled trial ofMBSRandbreast
cancer.23 This randomized controlled trial of MBSR in stage 0 to III
breast cancer (70%of participants had early stage 0 or I breast cancer)
found improvements in fear of recurrence, depression, anxiety, phys-
ical functioning, physical role functioning, energy, and pain,23 but the
sample sizewas small (N84), therewasno follow-upperiod, andno
correctional measures were applied for the large number of outcome
measures used. Earlier MSBR in cancer and breast cancer studies
showed improvements inmood including anxiety,10,11 stress,10,11 and
sleep quality.12
To our knowledge, this study was unique from otherMBSR and
cancer studies. Participants were recruited from The London Haven,
which is one of the day centers of the charity that provides free psy-
chological and integrative therapies for patients with breast cancer.
Participants received an average of 30 hours of Haven support before
study entry.
PATIENTS AND METHODS
A randomized controlled trial designwas used to test the hypothesis that there
would be a difference in the intervention group compared with controls as a
consequence of being exposed to MBSR in mood, disease-related quality of
life, including endocrine symptoms, andwell-being forwomenwith stage 0 to
III breast cancermeasured at baseline (T1; weeks2 to 0), weeks 8 to 12 (T2),
and weeks 12 to 14 (T3). An additional secondary study-specific analytic
question was as follows: Is there a dose-related effect from doing formal
mindfulness practice during the 8-week program?
Sample and Setting
Patients were recruited over 15 months from The Haven. Potentially
eligible patients were contacted by letter and interviewed, and eligibility was
strictly assessed by using the following inclusion criteria: women diagnosed
with stage 0 to III breast cancer, agedbetween18 and80 years,whowere aware
of their cancer diagnosis, able to complete questionnaires, within 2months to
2 years after the completion of surgery, chemotherapy, and/or radiotherapy.
Patients excluded were diagnosed with stage IV breast cancer, men, did not
speak English, could not give informed consent as a result of psychosis or
intellectual impairment, or suffered from substancemisuse, suicidal thoughts,
or current psychosis. The study gained approval from the National Health
Service’s Local Research Ethics Committee.
After patients provided signed informed consent, participants were allo-
cated to receive eitherMBSRor await-listed control. Randomassignmentwas
performed by operations director of the organization, who was independent
from the study, by using an externally computer-generated randomization
program in blocks of four, which ensured allocation concealment because no
clinician/researcher could anticipate or direct the allocation of participants.
The clinician-researcher conducting the study anddeliveringMBSRcouldnot
be blinded to the allocation of participants to either the treatment or control
group. Anonymized data were collected by a research assistant who was
blinded to group assignment and independent fromMBSR delivery.
Sample Size
From related data,10 the sample-size calculation was based on a differ-
ence in primary outcome (Profile ofMood States [POMS] score) of 13 points
with a standard deviation (SD) of 30. The use of results from nQuery Advisor
Version 5 (Statistical Solutions Software, Saugus, MA) indicated that the
recruitment of 85 participants per arm provided 80% power for a two-sided t
test by using a 5% level of significance. To allow for dropouts and nonatten-
dance, we planned to recruit 120 patients per arm for a total of 240 patients.
Adjustment for T1 covariates was likely to increase the statistical power.
Intervention: Mindfulness-Based Stress Reduction
The 8-week MSBR program closely followed that of Kabat-Zinn13 and
has been run in theUnited States for 30 years.24 The programaims to cultivate
mindfulness, which is defined as bringing complete attentionof the individual
to the experience that occurs in the present moment in a nonjudgemental or
accepting way.13,25-28 Mindfulness can be practiced as a valuable self-help
technique without requiring any belief system.
From a consensus within the literature,10-13 a standardized MBSR
program was divided into 8 weekly classes of 2 hours in length, except the
first and last classes were 2.25 hours in length, plus one 6-hour day of
mindfulness in week 6. The classes consisted of the following formal
mindfulness practices: a body scan, gentle and appropriate lying and
standing yoga-based stretches, sittingmeditation, some group discussions,
didactic teaching, and home practice on topics including perceptions of
and reactions to life events, stress physiology, andmindfulness in commu-
nication and everyday life. Home practice was delivered by four 45-minute
compact discs of formal mindfulness practices and a manual. Participants
were asked to practice for 40 to 45 minutes for 6 or 7 d/wk. Time and the
amount of formal home practice were recorded by using weekly record
sheets. The clinician/researcher was qualified as anMBSR instructor at the
University ofMassachusetts Center forMindfulness in 2004 and the Senior
Teacher Trainer of the clinician/researcher provided clinical supervision
during the study.
Between 2005 and 2006, a pilot feasibility 8-weekMSBR group was run
with 10 Haven staff and two women treated for breast cancer (who were not
Haven attendees). The pilot was designed to give the instructor practice run-
ning the program under clinical supervision and to resolve any practical
delivery problems. These data were not analyzed. After this pilot was run, 12
MBSR groups with 12 to 20 participants were run by the clinician-researcher.
In the autumn of 2006, an additionalMSBR group was run for the remaining
wait-listed control group. Participants on theMBSRprogramwith any study-
related concerns could contact the clinician-researcher during or after the
study period.
Wait-Listed Controls
Wait-listed controls continuedwith their lives as usual before participat-
ing inMSBR after the study period. Controls were offeredmeasurement tools
at T1, T2, and T3 while the experimental group had their MBSR program.
Outcome Measures
All outcome measures were completed at T1, T2, and T3. The primary
outcome was mood and measured by using the POMS (65-item).29 The
POMS total mood disturbance comprises subscales that evaluate anxiety,
depression, anger, vigor, fatigue, and confusion. Lower scores indicated an
improvement in mood.
Secondary outcomes included the following: Functional Assessment
of Cancer Therapy-Breast (FACT-B) 37-item (Version 4) scale,30 which
contains subscales of physical, social, emotional, and functional well-being
in addition to the 10-item breast-specific subscale, which included con-
cerns about body image, shortness of breath, and pain. The Functional
Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) scale,
which contains the aforementioned subscales of physical, social, emo-
tional, and functional well-being in addition to a 19-item endocrine-
specific subscale that measures menopausal symptoms, including hot
flashes, vaginal dryness, and loss of libido, and the WHO five-item
well-being questionnaire (WHO-5).31,32 Higher scores in the Functional
Assessment of Cancer Therapy and WHO-5 measures indicated an
improvement in quality of life or well-being. All previously mentioned
outcome measures were validated (J. Soulsby, personal communica-
tion, May 2003).29,30,32-35
Data Analysis
Thenumbers of questionnaires analyzed fromthe treatment and control
groups were 103 and 111 questionnaires, respectively. The numbers of ques-
tionnaires returned at T2 and T3 were 97 and 91 questionnaires, respectively,
Hoffman et al
1336 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 150.237.203.13 on February 2, 2017 from 150.237.203.013
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
in the treatment group and 109 and 106 questionnaires, respectively, in the
control group. The proration method (standard mean imputation) was used
to address missing data within questionnaires as advised in the questionnaire
manuals.33,36Whenwhole questionnairesweremissing at T2 or T3, datawere
imputed by using previous values carried forward. There were three instances
(two patients in the intervention group and one patient in the control group)
inwhichmore than20%ofdatawasmissing fromparticipants atT1, and thus,
according to rules set by the questionnaire manuals, their data was excluded
because it was too sparse to analyze. An intention-to-treat between-group
analysis was performed because results of participants were analyzed in the
groups towhich theywere randomly assigned.Data fromthePOMSandother
scales were analyzed with a repeated-measures analysis of variance model by
using SPSS version 18 software (SPSS, Chicago, IL). For each outcome vari-
able,measurementoccasionsT2andT3 formed thewithin-patients factor, the
measurementmadeatT1wasusedas a covariate, and treatment groupwas the
between-patients factor. In this model, the between-patients factor indicated
the treatment effect, and the interaction between the measurement occasion
and treatment group indicated whether the treatment effect differed between
T2 and T3. Treatment effects at T2 and T3 are presented as adjusted mean
differences and 95% CIs. The clinical significance of results for Functional
Assessment of Cancer Therapy scales and theWHO-5 are reported according
to questionnaire-specific criteria (B. Brown, personal communication, Febru-
ary 2008).37-39
To test whether hours of formal mindfulness practice done both in the
classroomandathomewereassociatedwith improvedoutcomesatT2andT3,
a series ofmultiple linear regressions was done separately for each outcome at
each time point. For each analysis, themeasurementmade at T1was included
as a covariate.
RESULTS
Sociodemographic and Clinical Characteristics
We recruited 229 women, and sociodemographic, clinical,
and medical treatment details are listed in Table 1. The mean (SD)
age was 49.0 years (9.26 years) in the experimental group and 50.1
years (9.14 years) in the control group. By using British socioeco-
nomic status classifications,most participants were classified in the
highest social class (73.7% of participants in the experimental
group and 78.3% of participants in the control group). Two hun-
dred fourteen women (93%), (mean age, 49 years) completed the
study, which indicated a lowdropout rate (theCONSORTdiagram
of the study is shown in Fig 1).
Quality-of-Life Measures
Therewereno significant between-groupdifferences foundatT1
for any of the scales.
Mood State
Therewere statistically significant differences between treatment
groups for POMS totalmood disturbance, anxiety, depression, anger,
vigor, fatigue, and confusion (Table 2). The T1-adjustedmean differ-
ences and 95% CIs at T2 and T3 suggested statistically significant
lowermood-state scores in the experimental group than in the control
group at both measurement occasions except for depression (T2
only), anger (T3 only), and confusion (T2 only). Therewere no statis-
tically significant interactions between treatment group andmeasure-
ment occasion.
No established methods for calculating levels of clinical signifi-
cance exist for POMS, and thus, this calculation was not undertaken
(B. Brown, personal communication, February 2008).
Secondary Outcomes
Disease-related quality-of-life and endocrine symptoms. Results
for quality of life were measured by using the breast-specific quality-
of-life scale FACT-B and the FACT-ES scale for endocrine symptoms.
Higher numbers indicated better scores on all FACT scales.
After adjustment for the outcome measurement made at T1,
there were statistically significant treatment effects for FACT-ES,
FACT-B, physical well-being, social well-being, emotional well-
being, and functional well-being (Table 3). Mean scores in the
experimental group compared with the control group were greater
at both T2 and T3 for all six measures (except social well-being
which was significant at T2 only). For emotional well-being, there
was some evidence that treatment effects at T3 were statistically
significantly greater that at T2. No other interactions were statisti-
cally significant.
The mean treatment effect was 7 for FACT-B at T2 and 8 for
FACT-BatT3,whichwere the sameas theminimumclinically impor-
tant difference of 7 to 8 reported in the literature.37
Well-being. After adjustment for T1 measurements, there were
statistically significant increases in the WHO-5 in the experimental
group comparedwith controls, and these were apparent at T2 and T3
(Table 3).
For the WHO-5, the minimum clinically important difference
has been suggested to be a change of 10%on standardized percentage
scores,whichareobtainedbymultiplying the rawscoresby four.37The
adjustedmeandifferences,which are listed inTable 3 andexpressed as
standardized percentage scores, were 8.04% at T2 and 8.60% at T3.
These scores were close to the minimum clinically important differ-
ence of 10%.
Dose-related effects of mindfulness. The mean (SD) number of
hours of formal home practice of mindfulness in the experimental
groupwas19.58hours (11.49hours)over8weeks,whichequates toan
average of 21 min/d. From their reports, participants changed their
behavior and complied with home practice. When the mean class-
roommindfulness practice timewas added (average of 12min/d over
8 weeks), 33 min/d of practice was undertaken. Attendance of MBSR
classes in the experimental groupwas high with amean (SD) of 17.45
hours (6.55 hours) over the course, averaging 2.18 h/wk. The mean
(SD) number of weekly sessions attended (excluding the 6-hour day)
was 6.26 sessions (2.12 sessions) of a possible eight sessions, which
suggested participants were motivated.
Increased hours of formal mindfulness classroom and home
practice in the experimental group was associated with improved
scores inPOMStotalmooddisturbanceatT3(P .004), anxietyatT3
(P  .01), anger at T2 (P  .005) and T3 (P  .02), vigor at T3
(P .02), fatigue at T3 (P .03), and confusion at T2 (P .04) and
T3 (P  .001). These increased hours were also associated with im-
proved scores inFACT-ESatT2 (P .05) andT3 (P .005), FACT-B
at T3 (P  .006), FACT physical well-being at T3 (P  .04), and
WHO-5 at T2 (P .01) andT3 (P .001). No serious adverse events
were reported in this study.
DISCUSSION
To our knowledge, this study was the largest adequately powered
trial to date that tested the effects of the MBSR program in women
with stage 0 to III breast cancer. Important findings from this study
MBSR in Mood, Quality of Life, and Well-Being in Stage 0 to III Breast Cancer
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included statistically significant improvements after MBSR com-
pared with those of controls in overall mood, anxiety, depression,
anger, vigor, fatigue and confusion, breast- and endocrine-related
quality of life, emotional, physical, social, and role functional well-
being, and general well-being. The improvement in mood rein-
forced and extended results found in other studies that evaluated
mood in patients with cancer after MBSR10,11 and in patients with
breast and prostate cancer.40 To our knowledge, our study is the
first to show significant benefits of MBSR on mood in cancer at 3
months. Carlson et al11 measured follow-up in outpatients with
cancer at 6 months, but positive changes were not maintained by
Table 1. Sociodemographic and Clinical Characteristics of Sample
at Baseline
Characteristic
Experimental
Group
(n  114)
Control Group
(n  115)
No. of
Patients %
No. of
Patients %
Age, years
Mean 49.0 50.1
SD 9.26 9.14
Social grade
AB: higher and intermediate managerial/
administrative/professional 84 74 90 78
C1: supervisory clerical junior managerial/
administrative/professional 20 18 16 14
C2: skilled manual workers 2 2 2 2
D: semiskilled and unskilled manual
workers 6 5 5 4
E: on state benefits, unemployed,
lowest-grade workers 2 2 2 2
Stage of breast cancer
0 11 10 6 5
I 34 30 45 39
II 47 41 47 41
III 22 20 17 15
Breast cancer is a recurrence 6 5 8 7
Surgery 113 99 115 100
Wide local excision/partial mastectomy, No.
of operations
Mean 0.75 0.93
SD 1 1
0 38 33 28 23
1 67 59 67 59
2 8 7 20 17
 3 1 1 0 0
Mastectomy, No. of operations
Mean 0.54 0.45
SD 1 1
0 57 50 68 59
1 52 46 40 34
2 5 4 5 4
Breast reconstruction, No. of operations
Mean 0.36 0.30
SD 1 1
0 83 73 87 76
1 24 21 22 19
2 5 4 5 4
3 1 1 1 1
4 1 1 0 0
Chemotherapy 67 59 60 52
Neoadjuvant chemotherapy 20 18 8 7
No. of neoadjuvant cycles
Mean 1.07 0.39
SD 2 1
Range 0-10 0-8
Adjuvant chemotherapy 54 47 56 49
No. of adjuvant cycles
Mean 3.03 3.01
SD 4 3
Range 0-12 0-8
Radiotherapy 92 81 84 73
(continued in next column)
Table 1. Sociodemographic and Clinical Characteristics of Sample
at Baseline (continued)
Characteristic
Experimental
Group
(n  114)
Control Group
(n  115)
No. of
Patients %
No. of
Patients %
Endocrine treatment
Yes 56 49 54 47
Total 112 113
Missing 2 2
Type of endocrine treatment frequency
Anastrozole 15 13 13 11
Goserelin 0 2 2
Letrozole 3 3 0
Tamoxifen 36 32 39 34
Toremifene
Not stated 1 1 0
Not applicable 57 50 59 51
Second type of endocrine treatment
Anastrozole 0 1 1
Goserelin 5 4 2 2
Megestrol acetate 0 0
Tamoxifen 0 0
Not applicable 107 94 110 96
Herceptin
Yes 4 4 3 3
Missing 2 2 1 1
Time between diagnosis of breast cancer
and random assignment, months
Mean 17.44 18.98
SD 13 15
Time between completion of surgery,
chemotherapy, and radiotherapy and
random assignment, months
Mean 9.27 9.50
SD 6 6
No. of additional hours of Haven program
attended
Before T1
Mean 30.09 31.48
SD 17 14
Between T1 and T2
Mean 0.97 0.68
SD 2 1
Between T2 and T3
Mean 0.59 0.32
SD 2 1
Abbreviations: SD, standard deviation; T1, baseline (weeks2 to 0); T2, weeks 8 to
12; T3, weeks 12 to 14.
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that time point. Future research should include the measurement
of longer-term follow-ups to determine the duration of the effects
of the MBSR intervention.
Significant improvements in anxiety reinforced and extended
findings from studies of anxiety and MBSR17,18 and anxiety in
cancer10,23 and breast cancer.23 One explanation is that the process
of becoming more aware of thoughts and feelings and relating to
them as mental events from a decentered perspective, rather than
as aspects of self or as true reflections of reality, can be applied to
anxious and depressed thoughts.23 The finding that MBSR im-
proves depression, anxiety, anger, confusion, fatigue, and vigor in
patients with breast cancer extended findings fromMBSR found in
outpatients with general cancer.10 The improvements in depres-
sion was an important finding that added to the evidence base not
only for MBSR for depression in breast cancer but also to the
effectiveness of mindfulness for depression.41 The T1 total mood
disturbance was worse than in earlier MBSR and general cancer
studies10 and in cancer norms,42 perhaps because our sample had
Contacted by letter (N = 643)
Nonresponders (n = 296)
Excluded
   Did not meet entry criteria
   Declined to participate
(n = 13)
(n = 3)
(n = 10)
Not interviewed
   Work
   Further cancer treatment
   Illness not cancer
   Other life events
   Too far to travel
   Times not suitable
   Moved away
   Not known
(n = 50)
(n = 7)
(n = 4)
(n = 6)
(n = 8)
(n = 7)
(n = 5)
(n = 3)
(n = 10)
Interviewed
Allocated to intervention
Received MBSR (5 or more classes)
Discontinued MBSR classes
   No classes
   One class
   Two to four classes
Reasons for discontinuing:
   Illness other than BC
   Breast cancer recurrence
   Too busy
   Other life events
   Work
   Did not want to be with others with BC
   Course not suitable
   Moved away
Dropped out of study
   Illness other than BC
   Breast cancer recurrence
   Work
   Did not want to be with others with BC
   Moved away
   Not known
(n = 11)
(n = 2)
(n = 1)
(n = 4)
(n = 2)
(n = 1)
(n = 1)
(n = 114)
(n = 95)
(n = 19)
(n = 5)
(n = 1)
(n = 13)
 
(n = 2)
(n = 2)
(n = 3)
(n = 3)
(n = 5)
(n = 2)
(n = 1)
(n = 1)
(n = 242)
Allocated to controls (n = 115)
Dropped out of study
   Illness other than BC
   Moved away
   Completing study 
      questionnaires too distressing
   Deceased
Analyzed 
   T1
   T2
   T3 
Excluded from analysis
(study dropouts)        
   Missing Questionnaire 1
 Data imputed at T2
 Data imputed at T3
 
(n = 111)
(n = 111)
(n = 111)
(n = 4)
(n = 4)
(n = 2)
(n = 5)
(n = 4)
(n = 1)
   (n = 1)
(n = 1)
(n = 1)
Replied
   Interested and eligible
   Interested but ineligible
   Declined
(n = 347)
(n = 290)
(n = 7)
(n = 50)
Consenting patients randomly assigned
(n = 229)
Analyzed 
   T1 
   T2
   T3                              
   Study dropouts included in 
   analysis as Questionnaire 1 
   was completed
Excluded from analysis 
   Missing Questionnaire 1
   > 20% data missing
Data imputed at T2
Data imputed at T3
 
(n = 103)
(n = 103)
(n = 103)
(n = 4)
(n = 7)
(n = 5)
(n = 2)
(n = 6)
(n = 12)
Fig 1. CONSORT diagram. BC,
breast cancer; MBSR, mindfulness-based
stress reduction.
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already identified themselves as needing help by coming to The Haven.
Theendofhospital treatmentisknownasacriticalpointforpsychological
problems4 and is a time when people are more likely to seek the help of
MBSR at an integrative center like The Haven. A previous psychosocial
supportive-expressive group-therapy intervention trial for patients with
metastatic breast cancer showed beneficial effects only among patients
whohadmoremooddisturbanceatT1.43Therefore, it ispossible that the
enrollment of patients with stage 0 to III breast cancer withmoremood
disturbanceinthisstudymayhaveresultedinthepositiveeffectsobserved.
To our knowledge, data of improvements in breast- and
endocrine-specific quality of life from MSBR were novel as were
the significant improvements in endocrine symptoms asmeasured
by the FACT-ES scale. This is an important finding for womenwho
take endocrine treatments for  5 years. Findings for improve-
ments in overall well-being extended positive findings of MBCT44
in cancer (N 25).
Participants showed a commitment to mindfulness practice
by practicing 33 min/d, which compared well with 30 to 32 min/d
in cancer (M. Speca, L.E. Carlson, personal communication, June
2008)10 and breast cancer,23 and all measurements were taken in
the same way to include both classroom time and home practice
combined. Most improvements were maintained, and some improve-
ments were further improved at 4 weeks post-MBSR completion. In-
creasedhoursof formalmindfulnesspredicted significant improvements
inmooddisturbance,anxiety,anger,vigor, fatigue,confusion,endocrine-
and breast-related quality of life, physical well-being, and general well-
being.Therewasnoother opportunity to learnmeditation atTheHaven
during the study. Key limitations of this study included the following
Table 2. Primary Outcome for POMS Total Mood Disturbance and Subscales and Estimates of Treatment Effects
Outcome Measure
Experimental (n  103) Control (n  111)
Difference Between Groups at T2
and T3 Adjusted for Baseline
Mean SD Mean SD Mean 95% CI
Total score
T1 total mood disturbance 43.65 34.73 49.23 39.37 NA
T2 total mood disturbance 30.02 31.60 48.08 39.89 15.30 23.75 to 6.86
T3 total mood disturbance 29.83 34.19 45.47 35.67 12.91 21.02 to 4.81
Interaction time  treatment group, P .558
Treatment group main effect, P  .001
Subscales
T1 tension/anxiety 13.16 7.20 13.42 7.24 NA
T2 tension/anxiety 10.32 7.0 13.36 7.20 2.93 4.67 to 1.20
T3 tension/anxiety 10.33 7.02 12.73 6.59 2.30 3.96 to 0.63
Interaction time  treatment group, P .493
Treatment group main effect, P  .001
T1 depression/dejection 12.79 10.76 15.70 12.79 NA
T2 depression/dejection 10.0 9.95 14.96 13.23 3.39 6.06 to 0.71
T3 depression/dejection 10.34 10.32 14.10 11.60 2.32 4.86 to 0.22
Interaction time  treatment group, P .365
Treatment group main effect, P .017
T1 anger/hostility 10.75 8.08 11.60 8.62 NA
T2 anger/hostility 8.78 7.57 11.11 8.88 1.96 3.96 to 0.05
T3 anger/hostility 7.87 6.72 11.04 8.95 2.69 4.44 to 0.95
Interaction time  treatment group, P .458
Treatment group main effect, P .005
T1 vigor/activity 14.31 6.53 14.06 6.19 NA
T2 vigor/activity 15.91 6.0 13.57 6.61 2.21 3.67 to 0.75
T3 vigor/activity 16.23 6.63 13.47 6.22 2.63 4.12 to 1.15
Interaction time  treatment group, P .606
Treatment group main effect, P  .001
T1 fatigue/inertia 11.17 6.64 11.75 7.20 NA
T2 fatigue/inertia 8.71 6.10 11.62 7.16 2.68 4.31 to 1.04
T3 fatigue/inertia 9.27 6.90 11.39 6.73 1.84 3.45 to 0.22
Interaction time  treatment group, P .324
Treatment group main effect, P .002
T1 confusion/bewilderment 10.11 5.58 10.65 5.57 NA
T2 confusion/bewilderment 8.13 4.71 10.33 5.30 1.91 3.01 to 0.81
T3 confusion/bewilderment 8.24 5.32 9.63 4.31 1.09 2.20 to 0.01
Interaction time  treatment group, P .141
Treatment group main effect, P .002
NOTE. For each outcome measure, repeated-measures ANOVA was used with time (T2 and T3) as the within-patients factor, treatment group as the
between-patients factor, and baseline measure (T1) as a covariate. The group  time interaction tested the null hypothesis that differences between groups at T2
and T3 were identical. The group effect tested whether there were significant differences in T2 and T3 between groups (ie, did the intervention have an impact?).
Mean differences were used to compare groups at T2 and T3 after adjustment for values at T1 as a covariate.
Abbreviations: NA, not applicable; POMS, Profile of Mood States; SD, standard deviation; T1, baseline (weeks 2 to 0); T2, weeks 8 to 12; T3, weeks 12 to 14.
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points: tensions of having a clinician-researcher role, although to reduce
thisbias, a researchassistanthandleddata.AfterMBSR,duringweeks9 to
12 of the follow-up period, there was no record kept of the time spent
practicingmindfulness. A self-report is a potentially biasedmeasure, and
cost effectiveness was not evaluated. The study setting was atypical of
widely available support services. Generalizability was limited to women
with stage 0 to III breast cancer who seek psychological services. Of
note, patients less inclined to join this study included people with
stage III disease and patients who received more chemotherapy
and hormone therapy.
The importance of this study is that it demonstrated, within the
boundaries of the limitations mentioned, statistically and clinically
significant improvements in breast-related quality of life, including
breast- andendocrine-specific symptoms, andgeneralwell-being.The
Table 3. Secondary Outcomes for FACT-B, FACT-ES, WHO-5, and Estimates of Treatment Effects
Outcome Measure
Experimental Group (n  103) Control Group (n  111)
Difference Between
Groups at T2 and T3
Adjusted for Baseline
No. of Patients Mean SD % No. of Patients Mean SD % Mean 95% CI
FACT-ES
T1 102 127.02 18.84 107 127.08 23.20 NA
T2 102 134.97 19.26 107 127.37 23.58 7.65 3.95 to 11.36
T3 102 135.34 19.54 107 127.42 21.26 7.98 4.46 to 11.49
Interaction time  treatment group, P .814
Treatment group main effect, P  .001
FACT-B
T1 101 96.57 17.22 106 96.68 21.05 NA
T2 101 103.56 17.91 106 96.84 21.14 6.81 3.48 to 10.14
T3 101 103.78 17.85 106 96.22 19.43 7.65 4.61 to 10.68
Interaction time  treatment group, P .493
Treatment group main effect, P  .001
FACT PWB
T1 102 21.88 4.29 111 21.89 4.35 NA
T2 102 22.86 4.22 111 21.84 4.54 1.03 0.19 to 1.87
T3 102 22.97 4.34 111 21.67 4.87 1.31 0.49 to 2.12
Interaction time  treatment group, P .521
Treatment group main effect, P .002
FACT SWB
T1 102 17.59 5.91 109 18.78 6.01 NA
T2 102 18.36 5.65 109 18.26 5.88 1.06 0.17 to 1.94
T3 102 18.09 5.81 109 18.30 5.75 0.71 0.24 to 1.65
Interaction time  treatment group, P .436
Treatment group main effect, P .032
FACT EWB
T1 102 16.91 3.84 109 15.97 4.58 NA
T2 102 18.14 3.82 109 16.59 4.40 0.93 0.09 to 1.78
T3 102 18.59 3.75 109 16.28 4.42 1.72 0.86 to 2.57
Interaction time  treatment group, P .042
Treatment group main effect, P .001
FACT FWB
T1 102 17.83 5.03 110 17.65 5.83 NA
T2 102 19.46 5.27 110 17.41 6.06 1.91 0.87 to 2.95
T3 102 19.45 5.32 110 17.53 5.37 1.80 0.77 to 2.83
Interaction time  treatment group, P .804
Treatment group main effect, P  .001
WHO-5
T1 103 13.04 4.48 52.2 111 12.53 4.68 50.1 NA
T2 103 14.91 4.23 59.6 111 12.60 4.92 50.4 2.01 1.00 to 3.01
T3 103 15.08 4.62 60.3 111 12.65 4.30 50.6 2.15 1.16 to 3.15
Interaction time  treatment group, P .768
Treatment group main effect, P  .001
NOTE. For each outcome measure, repeated-measures ANOVA was used with time (T2 and T3) as the within-patients factor, treatment group as the
between-patients factor, and baseline measure (T1) as a covariate. The group  time interaction tested the null hypothesis that differences between groups at T2
and T3 were identical. The group effect tested whether there were significant differences in T2 and T3 between groups (ie, Did the intervention have an impact?).
Mean differences were used to compare groups at T2 and T3 after adjustment for values at T1 as a covariate.
Abbreviations: EWB, emotional well-being subscale; FACT, Functional Assessment of Cancer Therapy; FACT-B, Functional Assessment of Cancer
Therapy–Breast; FACT-ES, Functional Assessment of Cancer Therapy–Endocrine Symptoms; FWB, functional well-being subscale; NA, not applicable; PWB,
physical well-being subscale; SD, standard deviation; T1, baseline (weeks 2 to 0); T2, weeks 8 to 12; T3, weeks 12 to 14; SWB, social well-being subscale;
WHO-5, WHO five-item well-being questionnaire.
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results of this study support the recommendation for breast cancer
survivors to useMBSR to enhancemood and quality of life including
endocrine symptoms.
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